This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tilly-Kiesi, M. Articles by Tikkanen, M. J. Search for Related Content PubMed PubMed Citation Articles by Tilly-Kiesi, M. Articles by Tikkanen, M. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cholesterol Peripheral Arterial Disease Hazardous Substances DB LOVASTATIN Social Bookmarking                         What's this?

Effects of Lovastatin on High-Density Lipoprotein Subfractions in Hypercholesterolemic Patients with Peripheral Vascular Disease

Third Department of Medicine, University of Helsinki

Severi P. Mattila

Third Department of Surgery, University of Helsinki, Helsinki, Finland

Matti J. Tikkanen

First Department of Medicine, University of Helsinki

The effects of lovastatin treatment on high-density lipoprotein subfractions (HDL₂ and HDL ₃) were investigated in 34 patients with severe peripheral vascular disease and type IIa or type IIb hyperlipoproteinemia by use of a density gradient ultracentrifugation method.

Lovastatin therapy caused greater percentage changes in HDL₂ than in HDL₃. In HDL₂ the increases of cholesterol, total lipid, apolipoprotein AI (apoAI) and apoliproprotein AII (apoAII) concentrations were 23% (p < 0.05), 28% (p < 0.01), 24% (p < 0.01) and 11 % (p < 0.01), respectively, in subjects with the type IIa phenotype. In patients with the type IIb phenotype the corresponding increases were 42% (p < 0.01), 44% (p < 0.01), 38% (p < 0.01) and 21% (p < 0.05), respectively. The apoAI/apoAII weight ratio in HDL₂ rose by 11% and by 13% in type IIa and type IIb patients, respectively.

The present results suggest that during lovastatin treatment the slight increase in serum HDL-cholesterol concentration was due, not to cholesterol enrichment by high-density lipoproteins, but more probably to an increase of the number of HDL particles. The observed changes were more pronounced in type IIb than in type IIa patients.

Angiology, Vol. 44, No. 2, 129-137 (1993)
DOI: 10.1177/000331979304400207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?